Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
Finberg, J.P.; Lamensdorf, I.; Weinstock, M.; Schwartz, M.; Youdim, M.B.
Advances in Neurology 80: 495-499
1999
ISSN/ISBN: 0091-3952 PMID: 10410762 Document Number: 502774
Document emailed within 1 workday
Related Documents
Schwarzschild, M.A. 2010: Rasagiline in Parkinson's disease New England Journal of Medicine 362(7): 658; Author Reply 658-659Strowd, L.C.; Lee, A.D.; Yosipovitch, G. 2012: Livedo reticularis associated with rasagiline (azilect) Journal of Drugs in Dermatology: Jdd 11(6): 764-765
Van Laar, T.; Boon, A.J.W.; Bloem, B.R. 2010: Rasagiline is not for all Parkinson disease patients: the ADAGIO study Nederlands Tijdschrift Voor Geneeskunde 154: A2496
Boryczka, S.; Wietrzyk, J.; Opolski, A. 2002: Synthesis and antiproliferative activity in vitro of new propargyl thioquinolines Die Pharmazie 57(3): 151-154
Na, L.-x.; Liu, X.; Meng, Z.-m.; Guan, Z.; Zhang, L.-h.; Yang, Z.-j. 2015: Design and synthesis of photoaffinity biotin labelled 2'-O-propargyl-guanosine Yao Xue Xue Bao 50(1): 59-63
Suphanklang, J.; Santimaleeworagun, W.; Supasyndh, O. 2015: Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature Journal of the Medical Association of Thailand 98(12): 1254-1257
Galivan, J.; Nimec, Z.; Rhee, M. 1987: Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine Cancer Research 47(20): 5256-5260
Duchêne-Marullaz, P. 1977: Pharmacology, clinical pharmacology and therapeutic effects of Royat's thermal gas Semaine des Hopitaux. Therapeutique 53(7-8): 361-362
Jackman, A.L.; Taylor, G.A.; O'Connor, B.M.; Bishop, J.A.; Moran, R.G.; Calvert, A.H. 1990: Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo Cancer Research 50(17): 5212-5218
Vyas, B. 2001: European Association of Clinical Pharmacology and Therapeutics--Fifth Congress. Clinical pharmacology: from molecule to society--bridging the gap via Man IDrugs: the investigational drugs journal 4(10): 1133-1137
Poulsen, H.Enghusen.; Schmitz, O.E.; Brøsen, K. 2002: Clinical pharmacology 2001--important events. The Danish Society of Clinical Pharmacology Ugeskrift for laeger 164(12): 1652
Cheng, Y.C.; Dutschman, G.E.; Starnes, M.C.; Fisher, M.H.; Nanavathi, N.T.; Nair, M.G. 1985: Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase Cancer Research 45(2): 598-600
Göres, E.; Kossowicz, J.; Schneider, H.-G. 2004: Propyphenazone. Pharmacology and use Medizinische Monatsschrift für Pharmazeuten 27(3): 72-76
Burks, T.F. 1980: Pharmacology in Arizona Arizona Medicine 37(2): 96-98
Buerke, M.; Darius, H.; Meyer, J. 2000: Pharmacology of NSAIDS Der Internist 41(1): 66
Offerhaus, L. 1979: The pharmacology of alcohol Nederlands Tijdschrift Voor Geneeskunde 123(29): 1243-1246
Hata, T. 2000: Drugs and pharmacology Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 115(6): 364
Mutschler, E. 1975: Pharmacology of psychopharmaceuticals Die Medizinische Welt 26(25): 1211-1214
Weirich, E.G. 1978: Pharmacology of dermatocorticoids (1.)[ Zeitschrift für Hautkrankheiten 53(6): 189-194
Kuhn, J.G. 1998: Pharmacology of irinotecan Oncology 12(8 Suppl. 6): 39-42